Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

INTRODUCTION: Circulating tumor DNA (ctDNA) testing may identify patients at high risk for recurrence following chemoradiation (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC). We evaluated the feasibility of ctDNA testing on a readily available commercial fixed-gene panel to predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Knapp, Brendan, Mezquita, Laura, Devarakonda, Siddhartha, Aldea, Mihaela, Waqar, Saiama N., Pepin, Kym, Ward, Jeffrey P., Botticella, Angela, Howarth, Karen, Knape, Charlene, Morris, Clive, Govindan, Ramaswamy, Besse, Benjamin, Morgensztern, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000093/
https://www.ncbi.nlm.nih.gov/pubmed/35419282
http://dx.doi.org/10.3389/fonc.2022.856132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000093/
https://www.ncbi.nlm.nih.gov/pubmed/35419282
http://dx.doi.org/10.3389/fonc.2022.856132

Ejemplares similares